Neuren 2024 results investor webinar on 28 February 2025
Released
Released
Announcement PDF
Neuren (NEU) – ASX Announcement
27 February 2025
Neuren 2024 results investor webinar on 28 February 2025
Investor Webinar | Friday, 28 Feb 2025 at 12.30 PM AEDT
You are invited to register using this link:
https://us06web.zoom.us/webinar/register/WN_R__Xh9A3SaCXTqBuqUVyyw
Participants may submit questions at registration or during the session
Thursday 27 February 2025, Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU), following
today’s confirmation of the DAYBUE™(trofinetide) royalty in Q4 2024 for inclusion in its audited financial
statements, will report its full-year 2024 financial results on Friday 28 February 2025 and Neuren’s
management will host an investor webinar at 12:30 Australian Eastern Daylight Time to discuss the
results. Registration for the webinar may be completed via the link above.
About Neuren
Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in
early childhood and have no or limited approved treatment options. Recognising the urgent unmet
need, all programs have been granted “orphan drug” designation in the United States. Orphan drug
designation provides incentives to encourage development of therapies for rare and serious diseases.
DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for
the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia
Pharmaceuticals Inc. for the development and commercialisation of trofinetide.
Neuren’s second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental
disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt
Hopkins syndrome and Angelman syndrome.
Contact:
investorrelations@neurenpharma.com
Jon Pilcher, CEO: +61 438 422 271
ASX Listing Rules information
This announcement was authorized to be given to the ASX by the CEO & Managing Director of Neuren
Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124
Forward-looking Statements
This announcement contains forward-looking statements that are subject to risks and uncertainties. Such
statements involve known and unknown risks and important factors that may cause the actual results,
performance or achievements of Neuren to be materially different from the statements in this
announcement.
1 of 1
Share your feedback
Discover